We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$2.19B
1-Year Est. Return
374.99%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$308M
Cap. Flow
% of AUM
18.12%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.42% |
| 2 | Miscellaneous | 9.68% |
| 3 | Financials | 1.51% |
| 4 | Technology | 0.08% |
| 5 | Industrials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Evolus
EOLS
$587M
| $230K | 0.01% |
55,859
+20,000
| +56% | +$96.9K |
|
252
Q32 Bio
QTTB
$447M
| $225K | 0.01% |
35,000
+15,000
| +75% | +$71.3K |
|
|
LGVN
253
Longeveron
LGVN
$21.4M
| $208K | 0.01% |
+20,000
| New | +$132K |
|
254
AnaptysBio
ANAB
$1.67B
| $205K | 0.01% |
+3,698
| New | +$199K |
|
|
CEPS
255
Cantor Equity Partners VI
CEPS
$153M
| $202K | 0.01% |
+20,000
| New | +$202K |
|
|
KALV
256
DELISTED
KalVista Pharmaceuticals
KALV
| $201K | 0.01% |
10,000
| – | – |
|
257
Kyverna Therapeutics
KYTX
$518M
| $194K | 0.01% |
22,428
-35,000
| -61% | -$292K |
|
258
Nuvation Bio
NUVB
$2.34B
| $187K | 0.01% |
+43,500
| New | +$242K |
|
259
Benitec Biopharma
BNTC
$428M
| $186K | 0.01% |
+17,500
| New | +$203K |
|
260
Lipocine
LPCN
$17.9M
| $185K | 0.01% |
+23,180
| New | +$202K |
|
261
Rallybio
RLYB
$89.3M
| $184K | 0.01% |
+20,535
| New | +$140K |
|
262
Rezolute
RZLT
$445M
| $179K | 0.01% |
58,679
+20,000
| +52% | +$60K |
|
|
QCLS
263
Q/C Technologies Inc
QCLS
$19.2M
| $173K | 0.01% |
+50,000
| New | +$203K |
|
264
Erasca
ERAS
$6.31B
| $162K | 0.01% |
+10,000
| New | +$118K |
|
265
Coya Therapeutics
COYA
$108M
| $161K | 0.01% |
+40,900
| New | +$191K |
|
266
Personalis
PSNL
$1.82B
| $159K | 0.01% |
+25,000
| New | +$211K |
|
267
SI-BONE Inc
SIBN
$861M
| $159K | 0.01% |
+12,580
| New | +$197K |
|
|
STLN
268
Starling Oncology
STLN
$629M
| $154K | 0.01% |
+50,000
| New | +$153K |
|
|
HELP
269
Cybin Inc
HELP
$890M
| $150K | 0.01% |
31,278
-207,112
| -87% | -$1.34M |
|
270
Neuronetics
STIM
$224M
| $145K | 0.01% |
+100,000
| New | +$159K |
|
271
Ardelyx
ARDX
$984M
| $143K | 0.01% |
+23,900
| New | +$158K |
|
272
InflaRx
IFRX
$329M
| $142K | 0.01% |
+158,271
| New | +$150K |
|
273
Achieve Life Sciences
ACHV
$834M
| $141K | 0.01% |
47,800
| – | – |
|
274
Voyager Therapeutics
VYGR
$218M
| $135K | 0.01% |
35,000
| – | – |
|
|
CMMB
275
Chemomab Therapeutics
CMMB
$19.9M
| $126K | 0.01% |
80,000
| – | – |
|
Similar funds
GAMH
RCAG
AF
AWM
TCM
WRBC
IAN
BOI
ADAR1 Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.
- ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
- ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
- ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
- ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
- ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
- ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
- ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.
Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.